Cost-effective optimized scleroglucan production by Sclerotium rolfsii ATCC 201126 at bioreactor scale. A quantity-quality assessment

Microbial exopolysaccharides: Classification, biosynthetic pathway, industrial extraction and commercial production to unveil its bioprospection: A comprehensive review

Polysaccharides, found universally in all living-species, exhibit diverse biochemical structures and play crucial roles in microorganisms, animals, and plants to defend against pathogens, environmental stress and climate-changing. Microbial exopolysaccharides are essential for cell adhesion and stress resilience and using them has notable advantages over synthetic polysaccharides. Exopolysaccharides have versatile structures and physicochemical properties, used in food systems, therapeutics, cosmetics, agriculture, and polymer industries. Immense economic and infrastructural constraints hinder its widespread commercial use, necessitating a deeper understanding of metabolic-pathways amidst changing environmental climate that influences the biomass composition of EPS-producing wild-microbes. Green and sustainable extraction of EPS from microbes followed by commercial product development has still not been exploited comprehensively. Yield of EPS production vary from 0.1 to 3 g/g of cell weight, influenced by fermentation conditions. Economic barriers, including substrate and processing costs, limit commercial viability. Key biosynthetic pathways involve glycosyltransferases enzymes, whose regulatory network gaps and substrate specificity remain areas for optimization. Addressing these could enhance yields and lower production costs. Review illustrates various microbial-exopolysaccharides, influencing factors of production, and offer valuable insights on the bioplastic, biofuel, agri-bioproduct, and biomedicine. But their bioprospecting potential is yet to be exhaustively explored, along with their pros and cons nor documented comprehensively in scientific literature.

Optimized scleroglucan production by Athelia rolfsii and in vitro Sclg-5-fluorouracil release investigations

Scleroglucan is a notable member of the β-glucan microbial polysaccharides with a long tradition of industrial and therapeutic use. The local strain, previously identified as Athelia rolfsii TEMG MH 236106 produced an appreciable amount of scleroglucan using glucose as a carbon source and yeast extract as a nitrogen source. Plackett-Burman design was employed to effectively screen critical medium composition, culture, and fermentation conditions. Athelia rolfsii TEMG MH 236106 produced the maximum amount of scleroglucan (18.12 g/L) with a 45.3 % glucose conversion. Out of the eleven variables, the most effective factors showing a high level of significance are as follows: glucose, yeast extract, citric acid, inoculum disc numbers, culture volume and incubation time. An update to maximize scleroglucan production in the central composite design for four parameters (glucose and yeast extract concentrations, disc number, medium volume and incubation time) with 31 runs was applied and the production of scleroglucan reached its maximum at 31.56 g/L with 78.9 % glucose conversion. Three models of Sclg-5-fluorouracil complexes have been employed to study in vitro drug release investigations. Hence, the Sclg-5-FU (5 and 10 mg/mL) models appeared to be the most suitable for drug administration due to their concentration and distribution within capsules.

Efficient Production of Scleroglucan by Sclerotium rolfsii and Insights Into Molecular Weight Modification by High-Pressure Homogenization

Scleroglucan is a non-ionic water-soluble polysaccharide, and has been widely used in the petroleum, food, medicine and cosmetics industries. Currently, scleroglucan is mainly produced by Sclerotium rolfsii. A higher level of scleroglucan (42.0 g/L) was previously obtained with S. rolfsii WSH-G01. However, the production of scleroglucan was reduced despite a higher glucose concentration remaining. Additionally, the molecular weight of scleroglucan was large, thus restricted its application. In this study, by adjusting the state of seeds inoculated, the degradation issue of scleroglucan during the fermentation process was solved. By comparing different fed-batch strategies, 66.6 g/L of scleroglucan was harvested by a two-dose fed-batch mode, with 53.3% glucose conversion ratio. To modify the molecular weight of scleroglucan, a combination method with HCl and high-pressure homogenization treatment was established. Finally, scleroglucan with molecular weight of 4.61 × 10⁵ Da was obtained. The developed approaches provide references for the biosynthesis and molecular weight modification of polysaccharides.

One-step production of functional branched oligoglucosides with coupled fermentation of Pichia pastoris GS115 and Sclerotium rolfsii WSH-G01

Endo-β-1,3-glucanase with high specific activity is a prerequisite for enzymatic preparation of valuable β-oligoglucosides. Heterologous expression in Pichia pastoris GS115 with error-prone PCR technology was implemented, and the mutant strain 7 N12 was obtained. The mutant endo-β-1,3-glucanase showed efficient specific activities for degrading curdlan (366 U mg^-1) and scleroglucan (274.5 U mg^-1). Thereafter, one-step production of functional branched oligoglucosides was established with coupled fermentation of Pichia pastoris and Sclerotium rolfsii. During the fermentation process, the endo-β-1,3-glucanase secreted by Pichia pastoris GS115 can efficiently hydrolyse scleroglucan metabolized by Sclerotium rolfsii WSH-G01. The maximum yields of β-oligoglucosides in the shake flasks and 7-L bioreactor reached 1.73 g L^-1 and 12.71 g L^-1, respectively, with polymerization degrees of 2-17. The successful implementation of heterologous expression with error-prone PCR and the coupled fermentation simplified the multi-step enzymatic β-oligoglucoside preparation procedures, which makes it a potential strategy for industrial production of functional oligosaccharides.